{"id":"W2056348171","doi":"10.1016/j.cgh.2011.04.031","title":"Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial","year":2011,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":170,"is_retracted":false,"has_abstract":false,"ca_institutions":"Robarts Clinical Trials","funders":"UCB Pharma","keywords":"Certolizumab pegol; Medicine; Placebo; Internal medicine; Clinical endpoint; Adverse effect; Randomized controlled trial; Clinical trial; Gastroenterology; Maintenance therapy; Surgery; Tumor necrosis factor alpha; Infliximab; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005255667,0.0003071513,0.001162426,0.00006593595,0.0001338698,0.000009890495,0.0002510961,0.0004379289,0.0001154079],"category_scores_gemma":[0.001642855,0.0002589855,0.0007627665,0.0000173637,0.001246691,0.000007403949,0.0001714072,0.0002268125,0.00001402753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000009247021,"about_ca_system_score_gemma":0.0001711717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005194976,"about_ca_topic_score_gemma":0.00008640507,"domain_scores_codex":[0.9963711,0.001317403,0.0009271814,0.0007485118,0.00006802779,0.0005677936],"domain_scores_gemma":[0.998313,0.000373548,0.0003571433,0.000425926,0.0001292061,0.0004012399],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9634282,0.0004245396,0.03281809,0.00002270047,0.0005868152,0.0004933206,0.00003123744,2.389606e-7,0.00001498319,0.0009138932,0.0009630861,0.0003029192],"study_design_scores_gemma":[0.9611504,0.001789541,0.03350968,0.000005864697,0.0005629257,0.0001047426,0.00002255876,0.00027324,0.00001520178,0.001617867,0.0007660938,0.0001818755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920885,0.0001444203,0.002719438,0.000547421,0.0009591111,0.003028434,0.00006871374,0.00002946704,0.0004145279],"genre_scores_gemma":[0.9953302,0.0001858232,0.0005785014,0.001347372,0.000503797,0.001666636,0.0000990695,0.00003261719,0.0002560337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003241683,"threshold_uncertainty_score":0.9999862,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02949072393060239,"score_gpt":0.3090283153474281,"score_spread":0.2795375914168257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}